SP4P.F · Achieve Life Sciences, Inc

-

Please sign in to comment on SP4P.F

1 Comment

Admin

4 years ago

Achieve Life Sciences, Inc is currently in a long term downtrend where the price is trading 18.2% below its 200 day moving average.

From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.

Achieve Life Sciences, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.

Its net income has dropped by 47.9% to $-5M since the same quarter in the previous year.

Finally, its free cash flow grew by 27.4% to $-2M since the same quarter in the previous year.

Based on the above factors, Achieve Life Sciences, Inc gets an overall score of 2/5.

ISIN	US0044685008
Sector	Healthcare
Industry	Biotechnology
Exchange	F
CurrencyCode	EUR

PE Ratio	None
Target Price	36.71
Beta	1.59
Market Cap	72M
Dividend Yield	None

ABOUT

Achieve Life Sciences, Inc

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sopharma AD and University of Bristol Achieve Life Sciences, Inc., which is headquartered in Vancouver, Canada.

SP4P.F · Achieve Life Sciences, Inc

-

Achieve Life Sciences, Inc

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Achieve Life Sciences, Inc using a moving average strategy